Urologic Oncology: Seminars and Original Investigations
-
Publication Venue For
-
Long term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer..
40:273.e1-273.e9.
2022
-
The role of neoadjuvant chemotherapy, lymph node dissection, and treatment delay in patients with muscle-invasive bladder cancer undergoing partial cystectomy..
39:496.e17-496.e24.
2021
-
Post-traumatic stress disorder symptoms in non-muscle-invasive bladder cancer survivors: A population-based study..
39:237.e7-237.e14.
2021
-
Trends in management of ureteral urothelial carcinoma and effects on survival: a hospital-based registry study..
39:194.e17-194.e24.
2021
-
Trends in palliative care interventions among patients with advanced bladder, prostate, or kidney cancer: A retrospective cohort study..
38:854.e1-854.e9.
2020
-
Predictors of adequate lymph node dissection in patients with non-muscle invasive bladder cancer undergoing radical cystectomy and effect on survival..
38:796.e7-796.e14.
2020
-
Positive surgical margins at radical prostatectomy in the United States: Institutional variations and predictive factors..
38:1.e17-1.e23.
2020
-
Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma and venous thrombus-Trends and effect on overall survival..
37:577.e9-577.e16.
2019
-
Socioeconomic status, race, and long-term outcomes after radical prostatectomy in an equal access health system: Results from the SEARCH database..
37:289.e11-289.e17.
2019
-
National trends and disparities of minimally invasive surgery for localized renal cancer, 2010 to 2015..
37:182.e17-182.e27.
2019
-
First postoperative PSA is associated with outcomes in patients with node positive prostate cancer: Results from the SEARCH database..
36:239.e17-239.e25.
2018
-
Post-radical prostatectomy management options for positive surgical margins: argument for observation..
27:92-96.
2009
-
Real-time quantitative RT-PCR assay of prostate-specific antigen and prostate-specific membrane antigen in peripheral blood for detection of prostate cancer micrometastasis..
26:634-640.
2008
-
New drug development in metastatic prostate cancer..
26:430-437.
2008
-
Statistical considerations for the design and analysis of Phase III clinical trials in prostate cancer..
26:300-307.
2008
-
Does a delay in initiating definitive therapy affect biochemical recurrence rates in men with clinically localized prostate cancer?.
25:196-200.
2007
-
Anterior rectal wall gastrointestinal stromal tumor presenting clinically as prostatic mass..
23:268-272.
2005
-
9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901..
22:398-403.
2004
-
Factors associated with blood loss during radical prostatectomy for localized prostate cancer in the prostate-specific antigen (PSA)-era: an overview of the Department of Defense (DOD) Center for Prostate Disease Research (CPDR) national database..
21:447-455.
2003
-
Predictors of extracapsular extension and positive margins in African American and white men..
21:33-38.
2003
-
Variables in predicting survival based on treating "PSA-only" relapse..
21:292-304.
2003
-
Outcome research: prostate cancer databases..
7:39-42.
2002
-
The role of radical prostatectomy in patients with pretreatment prostate-specific antigen > or = 40 ng/mL..
7:167-172.
2002
-
Introduction to Department of Defense Center for Prostate Disease Research Multicenter National Prostate Cancer Database, and analysis of changes in the PSA-era.
6:203-209.
2001
-
A long-term study of the efficacy of treatment of localized prostate cancer..
3:171-176.
1997
-
Comparative studies of prostate cancers among United States, Chinese, and Japanese patients: characterization of histopathology, tumor angiogenesis, neuroendocrine factors, and p53 protein accumulations..
1:51-63.
1995
-
Radical prostatectomy in men less than 50 years old..
1:80-83.
1995